Antiplatelet Therapy for Non–ST-Segment Elevation Myocardial Infarction in Complex “Real” Clinical Scenarios: A Consensus Document of the “Campania NSTEMI Study Group”

Angiology ◽  
2016 ◽  
Vol 68 (7) ◽  
pp. 598-607 ◽  
Author(s):  
Marino Scherillo ◽  
Plinio Cirillo ◽  
Dario Formigli ◽  
Giulio Bonzani ◽  
Paolo Calabrò ◽  
...  
1970 ◽  
Vol 1 (1) ◽  
pp. 49-55
Author(s):  
SC Kohli

Oral antiplatelet therapy plays an important role in treating patients with acute coronary syndrome (ACS), including patients with unstable angina (UA), non-ST segment elevation myocardial infarction (NSTEMI) and patients with ST-segment elevation myocardial infarction (STEMI). All antiplatelet drugs in addition to inhibiting acute arterial thrombosis have danger of interfering with the physiologic role of platelet hemostasis. Bleeding is a major factor in evaluating the utility of available and upcoming antiplatelet drugs and their combination regimes. The role of anti platelet agents in the treatment of ACS has undergone significant changes over the past several years. Aspirin, thienopyridines, and glycoprotein (GP) IIb/IIIa inhibitors are now standard parts of the treatment of STEMI, NSTEMI and UA whether an early invasive or an initial conservative strategy is chosen. Antiplatelet drugs have an important role in secondary prevention in the patients of ischaemic heart disease. Keywords: Acute Coronary Syndrome; antiplatelet therapy; thienopyridines. DOI: http://dx.doi.org/10.3126/njms.v1i1.5799   Nepal Journal of Medical Sciences. 2012; 1(1): 49-55


Sign in / Sign up

Export Citation Format

Share Document